Member Info for CHELSEA7

6.90/7.10

+3.70%

Again for 20k, could tick up soon

100k at 6.77....................150k at 6.733

For 50k

SCANCELL Retweeted
BIA
@BIA_UK
·
3h
Good morning New York!

The BIA is at
@IAmBiotech
's CEO & Investor Conference??

We are looking forward to seeing our members present over the next two days!

#BIOCEO20

Buys 93k

Sells 26k

Actual spread 5%

Just being light hearted Inan, lets get to 50p then I will happily discuss £8, lol.

Ruck/Inan, leave you guys to it, lol. Me can feel a silly row coming on.

Let yer now when we TICK UP!!

Hence Ruck, Vulpes PlanB,,,,,,,,,,,,

Yeah, good posts, we have been waiting for 7 years now to see it trialled, it was probably one of the main reasons people bought in here................in the meantime we need to get the SCIB1 trial dosing patients, deals on the TCR and Avidamab front and I wonder where CRUK are up to with SCIB2??

Well Inanaco, as I said we rose to 9.75 on the back of Vulpes initial investment at 5p, so no I won"t rely on Lozan or anybody over there.

Very happy to leave that to BOD

Fractionally Up, 60k at 6.74, 60-150k same 6.733

Just 9k

Hmmm, read my first post this morning.

Funding doesn"t have to be a dirty word, it is as you know an opportunity, and necessity.

For 70k,

Tremendous presentation, a mix of old and very new. I got loads from it, confidence too.

Inanaco................."".Funding ... Its to early to consider"".............Why do you say that?? I think it is worth considering, albeit after consideration I don"t think at this stage Moditope funding will not happen for a while yet.

Worth considering too because I don"t feel there is anything to fear, Scancell don"t seem to, nor should we. As I said earlier we went from 3.7p-9.75p during the period Vulpes took their stake in the last round, and we might just get a bigger surprise this time. Either way we are longing to see first patients dosed in U.S.A and we need more funding to ensure that trial gets going A.S.A.P in 25 patients and you never know early data could well be in time to boost a round for a further fundraise for MOD1 by the end of the year and further development of MOD2 and all the while hoping the SCIB2 trial starts enrolling patients soon.

Then we have the three collaborations!!!

Another target for MOD1, a good article................

https://www.medicinenet.com/renal_cell_carcinoma/views.htm

Over on NEX a 20k sell at 6.733

MMs still taking 150k at 6.733, unchanged

I actually think Martin Diggle has probably brought a few holders with him, hence the increase in the number of trades we see nowadays.

It just has that air about it that we felt last time, Scancell are ploughing on and funding seems the last of their problems, as would be the case with any well run company and even more so now that Vulpes are on board. I know i keep mentioning that but yes they are that important to us and many were very very critical of the business accumen of the BOD over time, and Vulpes have only filled that gap IMHO.

So for the first time in some time, what with the Interims, collaborations and the IND we are better placed to make our decisions then we were for quite some time.